PT-141 (Bremelanotide) vs TriMix
A side-by-side research comparison of PT-141 (Bremelanotide) and TriMix across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | PT-141 (Bremelanotide) | TriMix |
|---|---|---|
| Full name | Bremelanotide (PT-141 / Vyleesi) | TriMix (Papaverine + Phentolamine + Alprostadil) |
| Category | Sexual Health | Sexual Health |
| Status | FDA Approved | Compounded medication |
| Mechanism | MC4R agonist in hypothalamus activating central sexual arousal pathways. Increases dopaminergic signaling independent of vascular mechanisms. | Papaverine relaxes smooth muscle via PDE inhibition. Phentolamine blocks alpha-adrenergic receptors. Alprostadil (PGE1) directly stimulates cAMP production in cavernosal tissue. Together they produce reliable penile erection independent of arousal. |
| Molecular weight | 1,025 Da | Combination compound |
| Half-life | 2.7 hours | ~1-3 hours (local effect) |
| Bioavailability | High (SubQ) | Direct intracavernosal: ~100% |
| Typical dose | 1.75 mg | 0.1-0.5 mL (titrated) |
| Frequency | As needed, ~45 min before activity | As needed, max 3x/week |
| Route | Subcutaneous injection | Intracavernosal injection |
PT-141 (Bremelanotide) reported benefits
- Increased sexual desire
- Central arousal mechanism
- Works both sexes (research)
- Non-vascular
- Rapid onset
TriMix reported benefits
- Reliable erectile response
- Works when oral meds fail
- Rapid onset (5-15 min)
- Adjustable dosing
- No systemic cardiovascular effects
Related comparisons
Research and educational reference only. Not medical advice.